Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069886 | 0.71 | CSF1R (0.47) | CSF1RGRM5MAOBHSD11B1KDR | |
| SCHEMBL13912207 | 0.71 | CSF1R (0.47) | CSF1RGRM5HSD11B1 | |
| SCHEMBL6058835 | 0.65 | TSHR (0.40) | GSK3B | |
| SCHEMBL12133934 | 0.63 | CYP11B1 (0.60) | GSK3B | |
| SCHEMBL6919417 | 0.63 | GRM5 (0.65) | GRM5 | |
| SCHEMBL13817571 | 0.63 | KCNK3 (0.65) | MAPT | |
| SCHEMBL31687482 | 0.62 | MEN1 (0.64) | MAOB | |
| SCHEMBL28570990 | 0.62 | NQO2 (0.56) | GRM5MAOBMAPTGSK3B | |
| SCHEMBL29768537 | 0.62 | NQO2 (0.56) | GRM5MAOBMAPTGSK3B | |
| SCHEMBL23352226 | 0.62 | CYP11B1 (0.51) | GRM5GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933012-B2 | Glycopeptide antibiotic derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933012-B2 | Glycopeptide antibiotic derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2030982-A1 | GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | NR2C2, NR0B2, NR3C2 | SLC6A3 2404/4885KCNH2 2094/4885TAAR1 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.